MedPage Today on MSN
Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke
NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings of $239.5M for Q3 2025, representing 29% year-over-year revenue growth for WAKIX®. These results were driven by the highest ...
Toronto Life on MSN
The Influentials 2025
In a world first, Lipsman and his team in Sunnybrook’s Hurvitz Brain Sciences Program non-invasively breached the blood-brain ...
Before it met its demise 50 years ago, the ore freighter commissioned by Northwestern Mutual was the rock star of Great Lakes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback